Hutchison China Meditech Limited Total Voting Rights (2052S)
September 29 2017 - 1:02AM
UK Regulatory
TIDMHCM
RNS Number : 2052S
Hutchison China Meditech Limited
29 September 2017
Total Voting Rights
London: Friday, September 29, 2017: For information purposes,
Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM)
hereby notifies the market that as at September 29, 2017, the
issued share capital of Chi-Med consisted of 60,750,132 ordinary
shares of US$1.00 each, with each share carrying one right to vote
and with no shares held in treasury.
The above figure of 60,750,132 may be used by shareholders as
the denominator for the calculations by which they could determine
if they are required to notify their interest in, or a change to
their interest in, Chi-Med under the Financial Conduct Authority's
Disclosure Rules and Transparency Rules.
For illustrative purposes only, the 60,750,132 ordinary shares
would be equivalent to 60,750,132 CREST depositary interests (each
equating to one ordinary share) which are traded on AIM or, if the
CREST depositary interests were converted in their entirety,
equivalent to 121,500,264 American depositary shares (each equating
to one-half of one ordinary share) which are traded on Nasdaq.
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 0001). For more information,
please visit: www.chi-med.com.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President, Corporate Finance
& Development +852 2121 8200
U.K. & International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVREASNNADPXEEF
(END) Dow Jones Newswires
September 29, 2017 02:02 ET (06:02 GMT)
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From Apr 2024 to May 2024
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From May 2023 to May 2024